Results 191 to 200 of about 45,700 (265)

Nationwide implementation of heart failure therapies: National Heart Failure Center Accreditation Program (HF‐CAP) in China

European Journal of Heart Failure, EarlyView.
Nationwide implementation of heart failure therapies in China. ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CI, confidence interval; CV, cardiovascular; GDMT, guideline‐directed medical therapy; HF, heart failure; HF‐CAP, National Heart Failure Center Accreditation ...
Jingmin Zhou, Xuejuan Jin, Yamei Xu, Zhonglei Xie, Xiaotong Cui, Yanyan Wang, Hua Wang, Xinli Li, Yugang Dong, Yuhua Liao, Weimin Li, Alexandre Mebazaa, Jiefu Yang, Junbo Ge, on behalf of the Heart Failure Center Accreditation Program Investigators   +14 more
wiley   +1 more source

The Emerging Role of Aldosterone Synthase Inhibitors in Overcoming Renin-Angiotensin-Aldosterone System Therapy Limitations: A Narrative Review. [PDF]

Card Fail Rev
Patel SK, Teoh H, Saunthar A, Yau TM, Verma S.   +4 more
europepmc   +1 more source

Distinct blood volume and left ventricular adaptation to severe obesity in middle‐aged adults at risk for heart failure

European Journal of Heart Failure, EarlyView.
Obesity, blood volume and ventricular remodelling. BMI, body mass index; DEXA, dual‐energy X‐ray absorptiometry; IR, increased risk; LVEDV, left ventricular end‐diastolic volume; LVEDVi, left ventricular end‐diastolic volume index. Created in BioRender. Wakeham, D.
Joseph Campain, Denis J. Wakeham, Katrin Dias, James P. MacNamara, Mitchel Samels, Erin J Howden, Graeme Carrick‐Ranson, Michinari Hieda, Benjamin D. Levine, Satyam Sarma, Christopher M. Hearon Jr   +10 more
wiley   +1 more source

Deep phenotyping of heart failure with preserved ejection fraction through multi‐omics integration

European Journal of Heart Failure, EarlyView.
Deep phenotyping of of heart failure with preserved ejection fraction (HFpEF) through multi‐omics integration. AI, artificial intelligence. Aims Heart failure with preserved ejection fraction (HFpEF) has become the predominant form of heart failure and a leading cause of global cardiovascular morbidity and mortality.
Jakob Versnjak, Titus Kuehne, Pauline Fahjen, Nina Jovanovic, Ulrike Löber, Gabriele G. Schiattarella, Nicola Wilck, Holger Gerhardt, Dominik N. Müller, Frank Edelmann, Philipp Mertins, Roland Eils, Michael Gotthardt, Sofia K. Forslund, Benjamin Wild, Marcus Kelm   +15 more
wiley   +1 more source

Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study. [PDF]

Eur Heart J Cardiovasc Pharmacother
Chen YH, Fang YW, Chen MT, Liou HH, Tsai MH.   +4 more
europepmc   +1 more source

European Journal of Heart Failure expert consensus statement on transcatheter treatment of mitral regurgitation in heart failure

European Journal of Heart Failure, EarlyView.
The patient with SMR: From diagnostic assessment to treatment. Secondary mitral regurgitation (SMR) is highly prevalent in patients with heart failure (HF), associated with poor prognosis, and its treatment is typically preceded by implementing pharmacotherapy for HF as well as cardiac resynchronization therapy.
Christos Iliadis, Marianna Adamo, Volker Rudolph, Nicole Karam, Ralph Stephan von Bardeleben, Stefan D. Anker, Victoria Delgado, Jörg Hausleiter, Hannah Kempton, Marco Metra, Michael Böhm, Stephan Baldus   +11 more
wiley   +1 more source

Beta‐blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

European Journal of Heart Failure, EarlyView.
In total, 5084 patients from Swedish registries with both heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) were included. Confounding was handled by overlap weighting based on propensity scores for beta‐blocker use. Patients were followed up for 5 years, or until death, emigration from Sweden or
Benedikt N. Beer, Lina Benson, Christian Basile, Benedikt Schrage, Peter Moritz Becher, Stefan Blankenberg, Paulus Kirchhof, Barna Szabó‐Söderberg, Marco Metra, Anne Lindberg, Egidio Imbalzano, Giuseppe M. C. Rosano, Patric Karlström, Peter G.M. Mol, Raffaele Scorza, Lars H. Lund, Felix Lindberg, Gianluigi Savarese   +17 more
wiley   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Dibo P, Mareddy NSR, Kojima GSA, Ershed M, Obi OS, Razaq S, Kumar V.   +6 more
europepmc   +1 more source

An individual treatment effect approach to predict response to mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction

European Journal of Heart Failure, EarlyView.
Aims Mineralocorticoid receptor antagonists (MRAs) are often underused in patients with heart failure (HF) and reduced ejection fraction (HFrEF). Individual treatment effect (ITE) may assist physicians in making timely decisions about which patients are the best suited for personalized therapy.
Masatake Kobayashi, Kevin Duarte, João Pedro Ferreira, Guillaume Baudry, Luca Monzo, John J.V. McMurray, Dirk J Van Veldhuisen, Bertram Pitt, Faiez Zannad, Nicolas Girerd   +9 more
wiley   +1 more source

Association Between Mineralocorticoid Receptor Antagonist Use With Worsening Renal Function and Prognosis in Patients With Acute Heart Failure. [PDF]

J Am Heart Assoc
Fujimoto Y, Shiraishi Y, Nogi K, Kohsaka S, Kohno T, Kitamura M, Nagatomo Y, Ueda T, Nogi M, Ishihara S, Nakada Y, Kawakami R, Kitai T, Oishi S, Akiyama E, Suzuki S, Yamamoto M, Kida K, Okumura T, Yoshikawa T, Saito Y, Matsue Y.   +21 more
europepmc   +1 more source